CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 8-K Event Acquisition or sale completed
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Material agreement
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Shareholder vote results
- 4 Open-market buy Director bought 5,000 shares at an average $1.89 ($9,436)
- 4 Planned sale Chief Legal Officer sold 10,455 shares at $1.88 ($19,654)
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Grant or award Chief Financial Officer acquired 91,180 shares (grant or award)
- 4 Grant or award Co-Chief Executive Officer acquired 179,850 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 80,560 shares (grant or award)
Page 11 of 23 · 446 filings